FIHL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fidelis Insurance Holdings Ltd is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive developments such as hedge fund buying and share repurchase programs, the company's financial performance has significantly deteriorated YoY, and technical indicators do not suggest a strong entry point. Analysts' ratings are mixed, with some raising price targets but others expressing concerns about the company's exposure to property business and softening market conditions. Given the lack of clear positive momentum and the investor's preference for long-term stability, holding off on buying is the prudent choice.
The stock's MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 31.737, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the price is below the pivot level of 19.81, suggesting limited upward momentum. Support and resistance levels indicate a narrow trading range, with the stock currently near its support level (S1: 19.276).
Hedge funds are significantly increasing their buying activity, with a 244.72% increase in the last quarter.
The company has approved a $400 million share repurchase program and declared a dividend of $0.15 per share, signaling shareholder-friendly policies.
The combined ratio of 80.6% in Q4 2025 indicates operational efficiency in underwriting.
Financial performance in Q4 2025 shows a sharp decline, with revenue down 11.70% YoY, net income down 196.40% YoY, and EPS down 207.34% YoY.
Analysts have mixed views, with some downgrading the stock due to its above-average exposure to property business and concerns about a softening insurance market.
The stock experienced a 4.23% decline in regular market trading, reflecting weak investor sentiment.
In Q4 2025, Fidelis Insurance reported revenue of $600.9 million, down 11.70% YoY. Net income dropped to $117.8 million, a significant decline of 196.40% YoY. EPS fell to 1.17, down 207.34% YoY. Despite these declines, the company maintained a combined ratio of 80.6%, indicating operational efficiency in underwriting.
Analysts are divided on the stock. Keefe Bruyette maintains an Outperform rating with a price target of $26, while Goldman Sachs and JPMorgan express bearish views with Sell and Underweight ratings, citing concerns about the company's exposure to property business and a softening insurance market. Evercore ISI remains neutral but acknowledges the challenging market conditions for the P&C insurance sector.
